Imaging Probes for Precision Medicine in Alzheimer's Disease

About the Research Project
Program
Award Type
Postdoctoral Fellowship
Award Amount
$200,000
Active Dates
July 01, 2022 - June 30, 2024
Grant ID
A2022020F
Goals
Here I aim to develop and refine [18F]-labeled imaging tools to guide the clinical development of a new class of drugs with disease-modifying potential, the epichaperome targeting agents.
Summary
Matching the right patient to the right medicine is a goal of the future in medicine. In this proposal I aim to build tools that can be used to image and select those Alzheimer disease (AD) patients that are most likely to benefit from a new experimental medicine with disease-modifying potential. This medicine, PU-AD, developed by my laboratory, works by rebalancing cellular networks and brain circuits. In mouse models, it reverted cognitive dysfunction and is currently in clinical evaluation in AD and related disorders. Tools I develop here therefore have immediate translational potential.
Unique and Innovative
The [18F]-labeled epichaperome probe could serve as a companion diagnostic to the therapeutic PU-AD or other emerging epichaperome therapies. The probe will complement this therapeutic platform – consisting of drug candidate, biomarker and diagnostic – with our ultimate goal being precision medicine for AD and ADRD. In addition, imaging epichaperomes may have clear diagnostic implications as the spatial distribution of brain network dysfunction via epichaperome imaging, could offer valuable information for tracking and staging within individuals and groups across the AD spectrum.
Foreseeable Benefits
Application of imaging in human studies offers unique opportunities to understand pathophysiology and treatment. The epichaperome imaging probe may aid in determining the interaction of PU-AD with its target, in guiding initial dosing of epichaperome therapeutic agents, and in identifying patients most likely to benefit from epichaperome therapy. Importantly, this probe could be added to the currently available imaging biomarker portfolio for AD to capture the anticipated spatio-temporal progression of the disease from very early stage, facilitating early clinical intervention.
Grants
Related Grants
Alzheimer's Disease Research
Neurostimulation to Improve Depression and Memory in Dementia
Active Dates
July 01, 2024 - June 30, 2027
Principal Investigator
Davide Cappon, PhD
Neurostimulation to Improve Depression and Memory in Dementia
Active Dates
July 01, 2024 - June 30, 2027

Principal Investigator
Davide Cappon, PhD
Alzheimer's Disease Research
Unfolding Alzheimer's Tau Therapies: Near- and Long-Term Approaches
Active Dates
July 01, 2023 - June 30, 2026
Principal Investigator
Paul Seidler, PhD
Unfolding Alzheimer's Tau Therapies: Near- and Long-Term Approaches
Active Dates
July 01, 2023 - June 30, 2026

Principal Investigator
Paul Seidler, PhD
Alzheimer's Disease Research
A Human Brain-in-a-Dish Model to Investigate Disease Mechanisms of FTD
Active Dates
July 01, 2022 - June 30, 2025
Principal Investigator
Dominik Paquet, PhD
A Human Brain-in-a-Dish Model to Investigate Disease Mechanisms of FTD
Active Dates
July 01, 2022 - June 30, 2025

Principal Investigator
Dominik Paquet, PhD